П

FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287
Estimated average bur	den
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 193
or Section 30(h) of the Investment Company Act of 1940

1. Name and Addres	1 0		2. Issuer Name and Ticker or Trading Symbol <u>SUPERNUS PHARMACEUTICALS, INC.</u> [SUPN]		tionship of Reporting Per all applicable) Director	10% Owner				
(Last) C/O SUPERNU	(First) S PHARMAC	(Middle) EUTICALS, INC.	3. Date of Earliest Transaction (Month/Day/Year) 02/22/2024		Officer (give title below)	Other (specify below)				
9715 KEY WEST AVENUE			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	g (Check Applicable					
			-	X	Form filed by One Rep	orting Person				
(Street) ROCKVILLE	MD	20850			Form filed by More tha Person	n One Reporting				
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication	nsaction Indication						
			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										

1. Title of Security (Instr. 3)	Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
	Code V		v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock								117,089	D	

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Expiration			Expiration Date (Month/Day/Year)		4 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Director Stock Option (Right to Buy)	\$ 27.94	02/22/2024		А		8,252		(1)	02/22/2034	Common Stock	8,252	\$0	8,252	D	
Restricted Stock Units	(2)	02/22/2024		A		5,369		(3)	(3)	Common Stock	5,369	\$ 0	5,369	D	

Explanation of Responses:

1. The option vests on February 22, 2025.

2. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

3. These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025.

/s/ Timothy C. Dec, as attorney-in-fact

02/26/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.